*** Notice: For the protection of property rights, this catalog is available for online browsing only. Please drop us a line if you would like to receive a copiable version of this catalog. Thank You!
Presenters: Mark Watanabe, PharmD; Barbara Poddig, PharmD, BCPP; LaGenia Bailey, PharmD; Mark E. Schneiderhan, PharmD, BCPP
Describe the therapeutic goals of using typical antipsychotic agents; Understand the common side effects of typical antipsychotic agents; Identify characteristics of "High potency" vs "Low potency" antipsychotic agents.
Recognize and formally diagnose social phobia using DSM-IV; Differentiate social phobia from other primary and secondary anxiety disorders; Identify the disorders which tend to be commonly comorbid with social phobia; understand indications for drug therapy, cognitive behavior therapy, and combined treatment for social phobia; Describe classes of drugs most appropriate in treatment and first line treatments and follow-up treatment in case of non-response.
Presenters: Mark D. Watanabe, PharmD, PhD; S. Charles Schulz, MD; Peter F. Buckley, MD
Define the demographic characteristics of schizophrenia; Appreciate the core diagnostic features of schizophrenia; Discuss which conditions mimic the presentation of schizophrenia; Understand the role of ancillary tests and other information in differentiating schizophrenia from neurological conditions; Identify new drugs available for full syndrome of schizophrenia; Distinguish the difference between the effects of traditional drugs and new drugs; Describe the current theories proposed for the pathogenesis of schizophrenia and their implications for rational drug therapy.
Presenters: Stephen L. Huber, MS, RPh; Cynthia Radford; Steven M. Grunberg, MD
This program features leading healthcare professionals giving presentations on the latest advances in the management of the side effects of chemotherapy. Discussions will include information on pharmacoeconomics of antiemetic therapy in oncology and appropriate use of antiemetic therapy. Specific topics include: Enhancing the Value of Antiemetics in Oncology; Reimbursement Environment in Antiemetic Therapy; Challenges in Antiemetic Therapy.
Presenters: Kevin M. Furmaga, PharmD; Michael Koronkowski, PharmD; Vinod Kumar, MD, MRC
Topics include: Pathophysiology and Non-Cognitive Symptoms of Alzheimer's Disease; Cognitive Symptoms of Alzheimer's Disease; Future Directions in Drug Therapy for Alzheimer's Disease.
Program provides participants w/ an update on new guidelines for the management of asthma, roles that pharmacists can play in the treatment of patients w/ asthma, and the role that medications affecting leukotriene synthesis or action may play in therapy.
Presenters: John G. Bartlett, MD; John P. Phair, MD
Provide a background for understanding the pharmacology efficacy and potential utility of a new class of antiretroviral agents, the non-nucleoside reverse transcriptase inhibitors
Discussion on the status of recent initiatives to create a national standard for the routine documentation and transmission of clinical and billing information related to the delivery of pharmaceutical care between pharmacy providers and third-parties.
Presenters: Celeste Lindley, PharmD; Steven M. Grundberg, MD; John D. Hainsworth, MD; Stephen L. Huber, MS, RPh
Learn about determining the emetogenic potential for chemotherapy agents; review new class system and algorithm for determining emetogenic potential of combo chemotherapy regimens. Discussions include the rationale for stratification of antiemetic dosage based on the emetogenicicity of the chemotherapy regimen; appreciating the cost and revenue comparisons for the 5HT3 antiemetics based on dosing considerations and identifing strategies for enhancing the antiemetics in a variety of practice settings.
Presenters: Thomas O'Conner, PharmD, MBA; Michael A. Mancano, PharmD; Barbara Goppold, RPh
Identify the four basic types of pharmacoeconomic analyses; Discuss and categorize the types of relevant costs; Evaluate the criteria for a well designed pharmacoeconomic study; Interpret study results; Suggest the most appropriate treatment modality based upon study results; Identify the potential value and uses of pharmacoeconomic research in the managed care environment.
Presenters: Perry Cohen; Joseph Ober, Pharm.D; Sharon Montgomery, MA, RPh; J. Russell May, PharmD
Explains the evolution of managed care, discusses the important issues facing managed care including outcomes, disease management, and pharmacoeconomics; formulary development; explains the impact of the formulary on the pharmacist, hospital and community.
Presenters: Barry Kass, RPh, MBA; Judith Barr, ScD; Gerald E. Schumacher, PharmD, PhD
This program provides an introduction to health outcomes research with an examination of the links among structure, process, and outcomes in clinical interventions and health delivery systems. System-based and patient-centered outcomes will be discussed with administrative, clinical and economic examples drawn from therapeutic drug monitoring, DUR/DUE, and other pharmacy-related topics.
Presenters: Robert B. Supernaw, PharmD; Mary J. Ferrill, PharmD; Sian Carr-Lopez, PharmD
Hyperlipidemia: Reducing Risk by Reducing Cholesterol; Should We Be Treating Patients With Medication?; Hypertension and Cardiovascular Risk: Will Controlling Blood Pressure Reduce the Risk?
Presenters: Vanessa L. Kluth, PharmD; Melissa Cordell, RN; Ed Septimus, MD
Identify important factors when choosing the appropriate antimicrobial agent for a given infection; Describe the mechanism of action and spectrum of active aminoglycosides; Discuss rationale for once-daily dosing; State appropriate timing of drug sampling as it relates to aminoglycoside dosing; Understand the importance of the interpretation of results.
Presenters: Steven M. Grunberg, MD; John D. Hainsworth, MD; Paul J. Hesketh, MD; Jane Nolte, PharmD
Pharmacoeconomics of antiemetic therapy, oral antiemetics replacing IV antiemetics, appropriate use of antiemetic therapy, and the management of cisplatin-induced delayed emesis
Presenters: Bogomir M. Kuhar, PharmD; Jean-Venable 'Kelly' R. Goode, PharmD, BCPS; Kim Malone, BS
Describe current rationale and epidemiology of cholesterol management. Review cardiovascular risk factors and current NCEP guidelines for treatment. List treatment approaches to achieving NCEP goals. List drug strategies and the major adverse reactions in treating hyperlipidemia. List the benefits of a pharmacy-based lipid screening and monitoring program. Explain procedures necessary for making a hyperlipidemia clinic. Identify the strategies needed to implement & keep a pharmacy-based clinic. Develop a marketing plan for a pharmacy-based clinic.
Presenters: Barry Coleman, RPh (Moderator); T. L. Vordenbaumen, Sr., RPh; Orville A. Wagner; Dr. Jaime Kravzov
A prominent international faculty that will "explore the pharmacy implications of NAFTA with an emphasis on education and practice needs, as well as quality and pricing in drug manufacturing".
Presenters: Richard G. Fiscella, RPh, MPH; Richard A. Quinones, MD; Bruce I. Gaynes, OD, MS, PharmD
Define glaucoma and explain disease manifestation; List different treatment options available; Describe the traditional medical treatments available; Understand the new medical agents available and how they may change therapeutic options for the treatment of glaucoma.
Presenters: Walter J. Curran, Jr., MD; David S. Ettinger, MD; Chandra P. Belani, MD; Dawn Moose, MD
Integration of Chemotherapy and Radiation for Non-Small Cell Lung Cancer; New Drugs in Treatment of NSCLC; Recent Improvements in the Management of NSCLC; Management of Anorexia and Cachexia for Patients w/ NSCLC
Presenters: Art Matthys, RPh; William Letender, MS, RPh; Dave Mason, RPh; Loyd Allen, PhD
Define the terms pharmacy, manufacturing, compounding, and triad; Identify areas where pharmacists can solve non-compliance problems using compounding services; List the unique dosage forms that are available to healthcare professionals. Understand how pharmacists meet the unique needs of patients at their practice sites; List the factors that exempt pharmacists from the Federal Food and Drug and Cosmetic Act; Realize the value of compounding services in terms of patient compliance and patient needs. Identify areas of practice could potentially benefit compounding; Select a course of action to take when filling a compounded prescription .
Presenters: R. Keith Campbell, RPh, FASHP, CDE; Julie C. Oki, PharmD, BCPS
Provide an update on the treatment of diabetes, including a review of the rationale for and means of achieving optimal glycemic control. Specific topics covered include: Discussion of the rationale for achieving optimal glycemic control in both type I and type II diabetic patients; Recent advances which may aid in achieving optimal glycemic control in type II diabetic patients; Methods to improve glycemic control in patients with type I diabetes.
Presenters: Mickey Smith, RPh, PhD; Jack Fincham, RPh, PhD; J. Lyle Bootman, RPh, PhD; Kent Summers, RPh, PhD; Albert I. Wertheimer, RPh, PhD
Describes the methods of detecting and predicting non-compliance, identifies the economic consequences of non-compliance to healthcare generally and in pharmacy practice, and discusses how to choose interventions best suited to enhance compliance.
Presenters: J. Herbert Patterson, PharmD; Michael B. Bottorff, PharmD; Barry Bleske, PharmD
Pathophysiology of heart failure and it's role in contributing to the morbiity and mortality of heart failure; be able to identify the most appropriate therapy for a patient to optimize outcomes; when a specific therapy is contraindicated, be able to identify alternate appropriate therapies to optimize therapeutic outcomes. Be able to list potential drug therapies that may be useful for heart failure.
Presenters: Frederick Pfeiffer, PharmD; Richard Herrier, PharmD, CPE
Assess the impact of medication nonadherance to the overall cost of healthcare in the US; Determine the need for patient education regarding medications for hypertension as it relates to drug defaulting; Determine the role of common annoying side effects with diuretics in the perpetuation of therapeutic nonadherance; Describe three misconceptions regarding compliance issues; List three main factors that are required for optimal patient compliance.
Presenters: Edward P. Armstrong, PharmD; Frederick Pfeiffer, RPh, MS, PharmD; Tim Sawyers, RPh, MBA, CDE
Provide information for using claims data to assess drug therapy; Analyze claims data to determine non-adherence to chronic medications; Understand how to access medical and pharmacy claims; Differentiate medical from pharmacy claims data and report generation; Identify specific depressions management problems in a managed care setting.